Show simple item record

dc.contributor.authorÖrnolfsson, Kristjan T
dc.contributor.authorLund, Sigrun H
dc.contributor.authorOlafsson, Sigurdur
dc.contributor.authorBergmann, Ottar M
dc.contributor.authorBjörnsson, Einar S
dc.date.accessioned2019-06-26T13:46:50Z
dc.date.available2019-06-26T13:46:50Z
dc.date.issued2019-05
dc.date.submitted2019-06
dc.identifier.citationBiochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study. 2019, 54(5):609-616 Scand J Gastroenterolen_US
dc.identifier.issn1502-7708
dc.identifier.pmid31074667
dc.identifier.doi10.1080/00365521.2019.1606931
dc.identifier.urihttp://hdl.handle.net/2336/620963
dc.descriptionTo access publisher's full text version of this article click on the hyperlink belowen_US
dc.description.abstractObjective: To assess the proportion of PBC patients with a biochemical response to ursodeoxycholic acid (UDCA) in a population-based cohort and the association of biochemical response with outcomes. Methods: All patients diagnosed with PBC in Iceland from 1991-2015 were identified. Patients taking UDCA for an adequate period of time were analyzed for treatment response according to the Barcelona, Paris I, Paris II and Toronto criteria and outcomes. Results: Overall 182 females and 40 males were diagnosed with PBC and 135 patients were treated with UDCA. Overall 99 (73%) patients had adequate data on UDCA treatment and results of liver tests to assess biochemical response according to the Barcelona criteria, 95 (70%) according to the Toronto criterion and 85 (63%) according to the Paris I and II criteria. In all 74% (n = 63), 67% (n = 64), 54% (n = 53) and 46% (n = 39) responded to treatment according to the Paris I, Toronto, Barcelona and Paris II criteria. Among nonresponders according to the Paris I, Toronto, Paris II and Barcelona criteria, 50%, 39%, 33% and 30% developed cirrhosis versus 10%, 6%, 5% and 11% of responders, HR 5.36 (p = .002), 6.61 (p = .002), 10.94 (p = .003) and 2.21(p = .11), respectively. Age-adjusted mortality was significantly lower among responders according to the Paris I and Paris II criteria, HR 0.33 (p = .02) and 0.31 (p = .02), respectively. Conclusion: Development of cirrhosis and higher mortality was significantly associated with a lack of biochemical response to UDCA. Frequent development of cirrhosis and increased mortality in nonresponders underlines the need for a more effective therapy than UDCA for this sizeable subgroup of patients.en_US
dc.description.sponsorshipIntercept Pharmaceuticals, Inc.en_US
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.relation.urlhttps://www.tandfonline.com/doi/full/10.1080/00365521.2019.1606931en_US
dc.subjectBarcelona criteriaen_US
dc.subjectParis criteriaen_US
dc.subjectPrimary biliary cholangitisen_US
dc.subjectUDCAen_US
dc.subjectbiochemical responseen_US
dc.subjectnationwideen_US
dc.subjectpopulation-baseden_US
dc.subjectprimary biliary cirrhosisen_US
dc.subjecttoronto criterionen_US
dc.subjectursodeoxycholic aciden_US
dc.subjectGallrásen_US
dc.subjectBólguren_US
dc.subjectLyfjameðferðen_US
dc.subject.meshLiver Cirrhosis, Biliaryen_US
dc.subject.meshCholangitisen_US
dc.titleBiochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.en_US
dc.typeArticleen_US
dc.contributor.department1 a Faculty of Medicine , University of Iceland, Reykjavík, Iceland. 2 b Division of Gastroenterology and Hepatology , Landspitali The National University Hospital of Iceland , Reykjavík , Iceland.en_US
dc.identifier.journalScandinavian journal of gastroenterologyen_US
dc.rights.accessLandspitali Access - LSH-aðganguren_US
dc.departmentcodeGAS12
dc.source.journaltitleScandinavian journal of gastroenterology


This item appears in the following Collection(s)

Show simple item record